干旱区生态环境知识资源中心(Arid): 重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察

Arid

	重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察
其他题名	A controlled clinical study on the efficacy of recombinant human interleukin - 2 in the treatment of pulmonary tuberculosis
	初乃惠 1; 朱莉贞 1; 叶志忠 2; 苑松林 3; 王静云 4; 许家琏 5; 马丽萍 1
来源期刊	中华结核和呼吸杂志
ISSN	1001-0939
出版年	2003
卷号	26 期号:9 页码:548-551
中文摘要	目的研究和评价重组人白细胞介素-2(IL-2)辅助治疗肺结核病的疗效。方法将209例复治菌阳肺结核患者，采用计算机随机分组方法分为：治疗组106例，采用3PaZ(TH)L_2VE(AK)+IL-2/4PaL_2V方案化疗(Pa：力克肺疾，Z：吡嗪酰胺，TH：丙硫异烟胺，L：利福喷汀，V：左氧氟沙星，AK：阿米卡星，E：乙胺丁醇)；对照组103例，采用3PaZ(TH)L_2VE(AK)/4PaL_2V方案进行短程化疗。结果完成疗程可评价疗效者203例，其中治疗组103例，对照组100例。治疗第1、2个月治疗组和对照组痰菌阴转率分别为33.3%、7.2%和69.4%、44.9%，差异有非常显著性意义(P < 0.01)。治疗结束时治疗组和对照组显效率分别为64.1%和36.0%，差异有非常显著性意义(P < 0.001)。治疗组治疗3和7个月时CD_4、CD_4/CD_8和NK细胞较对照组提高，差异有非常显著性意义(P M < 0.01)。治疗3个月时治疗组IL-2可溶性受体(sIL-2R)较对照组降低，两组比较差异有显著性(P < 0.05)。无严重不良反应发生。结论重组人IL-2可辅助治疗肺结核，是一种安全、可靠的生物制剂。
英文摘要	Objective To study and evaluate the efficacy and safety of recombinnnt human interleukin -2(IL-2) in the treatment of pulmonary tuberculosis. Methods Two hundred and nine cases with re-treated Mycobacterium tuberculosis-posilive pulmonary tuberculosis were randomly divided into a trial group (106 oases, treated with 3PaZ(TH) L2VE( AK) + IL-2/4PaL2V) and a control group (103 cases, treated with 3PaZ(TH)L,VE( AK)/4PaL2V). The efficacy of 203 cases was available for evaluation when the course was completed (trial group 103 cases, control group 100 cases). Results The sputum smear-negative conversion rates at the 1st and the 2nd month of therapy were 33. 3% and 69. 4% in the trial group, and 7. 2% and 44. 9% in the control group (P<0. 01). At the completion of the therapy, the X-ray resolution rates were 64. 1% and 36.0% respectively for the trial and the control groups, the difference being significant (P<0. 001). There were significant differences in CD4 T cells, the ratio of CD4/CDg and NK cells between the two groups (P < 0. 01). The level of soluble interleukin-2 receptor ( sIL-2R) was significantly different between the two groups after treatment for 3 months (P < 0. 05). IL-2 associated side effects were rare and mild. Conclusion As an effective and relatively safe biological agent, IL-2 can be added to the standard chemotherapy for pulmonary tuberculosis.
中文关键词	白细胞介素2 ; 结核，肺 ; 分支杆菌，结核 ; 药物疗法
英文关键词	interleukin-2 tuberculosis, pulmonary Mycobacterium tuberculosis drug therapy
语种	中文
国家	中国
收录类别	CSCD
WOS类目	MEDICINE GENERAL INTERNAL
WOS研究方向	General & Internal Medicine
CSCD记录号	CSCD:1260842
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/204722
作者单位	1.北京市结核病胸部肿瘤研究所, 101149; 2.厦门市第二医院; 3.天津市肺科医院; 4.沈阳市胸科医院; 5.上海市肺科医院
推荐引用方式 GB/T 7714	初乃惠,朱莉贞,叶志忠,等. 重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察[J],2003,26(9):548-551.
APA	初乃惠.,朱莉贞.,叶志忠.,苑松林.,王静云.,...&马丽萍.(2003).重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察.中华结核和呼吸杂志,26(9),548-551.
MLA	初乃惠,et al."重组人白细胞介素-2辅助治疗复治肺结核近期疗效观察".中华结核和呼吸杂志 26.9(2003):548-551.